• Explore /
  • Poster
  • / A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.

A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.

Abstract Poster

Authors

Saad Usmani

Saad Zafar Usmani

Memorial Sloan Kettering Cancer Center, New York, NY

Saad Zafar Usmani , Michał Mielnik , Ja Min Byun , Aránzazu Alonso Alonso , Al-Ola A. Abdallah , Mamta Garg , HANG QUACH , Chang-Ki Min , Wojciech Janowski , Enrique M. Ocio , Katja Weisel , Albert Oriol , Irwindeep Sandhu , Paula Rodríguez-Otero , Karthik Ramasamy , Jacqueline L. Egger , Danae Williams , Jie Ma , Morrys C. Kaisermann , Marek Hus

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT04091126

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8018)

DOI

10.1200/JCO.2023.41.16_suppl.8018

Abstract #

8018

Poster Bd #

10

Abstract Disclosures

Similar Posters

First Author: Saad Zafar Usmani

First Author: Evangelos Terpos

First Author: Pieter Sonneveld

First Author: Andree Kurniawan